Alpa Laboratories Ltd

For the fifth consecutive session, Alpa Laboratories Ltd closed lower, hitting a fresh 52-week low of Rs 54.1 on 27 Mar 2026. This marks a steep 54.5% decline from its 52-week high of Rs 118.8, underscoring sustained selling pressure amid a challenging market backdrop.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Despite a broader market rally, Alpa Laboratories Ltd has plunged to its lowest price in 52 weeks, closing near Rs 54.56 on 23 Mar 2026. This decline comes amid a backdrop of weakening financial performance and persistent selling pressure that has pushed the stock down by nearly 49% over the past year.

Alpa Laboratories Ltd has reached a new 52-week low, reflecting a sustained decline in its share price amid broader market gains. The stock’s recent performance highlights ongoing concerns within the Pharmaceuticals & Biotechnology sector, with the share price now trading below all key moving averages.

Alpa Laboratories Ltd has touched a new 52-week low of Rs.54.56 today, marking a significant decline in its stock price amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial performance and market sentiment.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 17 Nov 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 13 March 2026, providing investors with the latest insights into its performance and prospects.

Alpa Laboratories Ltd has reached a new 52-week low, reflecting ongoing pressures in its share price as it closed at Rs 62.85, marking a significant decline from its peak of Rs 120.5 over the past year. This development underscores the challenges faced by the company within the Pharmaceuticals & Biotechnology sector amid a broader market downturn.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing challenges reflected in its financial and market performance.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing underperformance relative to broader market indices and sector peers.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Alpa Laboratories Ltd., the Indore-based pharmaceutical formulations manufacturer, reported a sequential profit recovery in Q3 FY26 with net profit of ₹1.90 crores, marking a dramatic 1,627.27% quarter-on-quarter surge from the near-zero ₹0.11 crores in Q2 FY26. However, the year-on-year comparison reveals a concerning 78.65% decline from ₹8.90 crores in Q3 FY24, underscoring persistent operational challenges that have plagued the micro-cap pharmaceutical company throughout FY26.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 January 2026, providing investors with an up-to-date view of its performance and outlook.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.63.76, marking a significant decline amid broader market pressures and company-specific performance issues.

Alpa Laboratories Ltd has declined to a fresh 52-week low of Rs.67.83, marking a significant downturn amid broader market fluctuations and company-specific performance issues. The stock’s recent slide reflects ongoing pressures in the Pharmaceuticals & Biotechnology sector, with the share price now trading well below all key moving averages.

Alpa Laboratories Ltd’s stock declined sharply to a fresh 52-week low of Rs.68.16 on 19 Jan 2026, marking a significant drop amid ongoing challenges in both its long-term and recent financial performance. The stock’s fall comes despite a broadly stable market environment, with the Sensex closing down 0.66% but still near its 52-week high.